Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma

Lin Lu; Lei Xia; Xinhong Shi; Yingying Dai; Zipeng Wu; Yue Shi; Yingying Jiang; Yiling Liu; Yuxin Ma; Shuyi Hu; Ruofan Yu; Tianyi Liu; Caolu Liu; Jingwen Li; Guochun Cao; Delin Liu; Fei Yan; Jinghua Zhu; Xiaohua Wang; Lijun Zhao; Cheng Chen

doi:10.1002/ctm2.70377

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (6) : e70377 DOI: 10.1002/ctm2.70377

LETTER TO THE JOURNAL

Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma

Author information +

History +

PDF

Cite this article

Download citation ▾

Lin Lu, Lei Xia, Xinhong Shi, Yingying Dai, Zipeng Wu, Yue Shi, Yingying Jiang, Yiling Liu, Yuxin Ma, Shuyi Hu, Ruofan Yu, Tianyi Liu, Caolu Liu, Jingwen Li, Guochun Cao, Delin Liu, Fei Yan, Jinghua Zhu, Xiaohua Wang, Lijun Zhao, Cheng Chen. Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma. Clinical and Translational Medicine, 2025, 15(6): e70377 DOI:10.1002/ctm2.70377

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Chen R, Zheng R, Zhang S, et al. Patterns and trends in esophageal cancer incidence and mortality in China: an analysis based on cancer registry data. J Natl Cancer Cent. 2023; 3(1): 21-27.

[2]	Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014; 32(5): 385-391.

[3]	Yang H, Liu H, Chen Y, et al. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: the NEOCRTEC5010 Randomized Clinical Trial. JAMA Surg. 2021; 156(8): 721-729.

[4]	Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 359(9319): 1727-1733.

[5]	Zhang W, Wang P, Pang Q. Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. Ann Transl Med. 2020; 8(18): 1193.

[6]	Liu J, Li J, Lin W, et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study. Int J Cancer. 2022; 151(1): 128-137.

[7]	Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. Nat Med. 2024; 30(9): 2549-2557.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.